Elucidation of anticoagulant and anti-inflammatory effects of each domain in Recombinant Human Soluble Thrombomodulin

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K09251
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55030:Cardiovascular surgery-related
• Research Institution: Teikyo University
• Principal Investigator: Ikeda Tsukasa 帝京大学, 医学部, 助手 (10768170)
• Co-Investigator(Kenkyū-buntansha): 内山 雅照 帝京大学, 医学部, 講師 (60713295)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: トロンボモジュリン / 心臓移植 / 制御性T細胞 / 血管内皮 / 生着延長 / リコモジュリン

Outline of Final Research Achievements

Untreated and D2-exposed CBA recipients acutely rejected C57BL/6 cardiac
allografts within 9 days. Administration of D3 resulted in modest prolongation of allograft survival, and administration of D1 significantly prolonged allograft survival. Histologic studies showed that myocardial damage of allografts from D1- and D3-exposed CBA recipients was controlled compared with that of untreated recipients. In particular, the CD4+CD25+Foxp3+ cell population in the splenocytes of D1-exposed CBA recipients was increased.

Free Research Field

移植免疫学

Academic Significance and Societal Importance of the Research Achievements

当検討によって、トロンボモジュリンを構成するD1が制御性T細胞の誘導や、IFN-gamma産生抑制能を持ち、微小循環障害抑制による慢性拒絶反応の制御に寄与する可能性があると考えられた。